The UPS is the major pathway for protein degradation in eukaryotic cells 1 . Proteins are covalently tagged by the attachment of a polyubiquitin chain leading to rapid binding and hydrolysis by the 26S proteasome. This large (66-subunit) ATP-dependent proteolytic complex binds ubiquitinated proteins via receptor subunits on its 19S regulatory particle and then the ATPase complexes unfold and translocate the polypeptides into the 20S core particle where they are digested to small peptides by its six peptidase sites 2-4 . The proteasome's ability to hydrolyze short peptides can be stimulated by agents that cause cAMP accumulation or by treatment with pure protein kinase A (PKA) [5] [6] [7] . The accumulation of ubiquitinated protein inclusions in neurodegenerative diseases 8 suggests that defects exist in 26S proteasomemediated clearance in affected neurons, and in support of this, tau from people with Alzheimer's disease has been shown to be polyubiquitinated at several sites 9-11 and several studies have implicated UPS dysfunction in response to tauopathy [12] [13] [14] [15] [16] [17] . Herein, we demonstrate that pharmacological agents that raise cAMP in the brain and activate PKA can phosphorylate proteasome subunits, enhance proteasome activity, promote clearance of abnormal tau and improve cognition.
The UPS is the major pathway for protein degradation in eukaryotic cells 1 . Proteins are covalently tagged by the attachment of a polyubiquitin chain leading to rapid binding and hydrolysis by the 26S proteasome. This large (66-subunit) ATP-dependent proteolytic complex binds ubiquitinated proteins via receptor subunits on its 19S regulatory particle and then the ATPase complexes unfold and translocate the polypeptides into the 20S core particle where they are digested to small peptides by its six peptidase sites [2] [3] [4] . The proteasome's ability to hydrolyze short peptides can be stimulated by agents that cause cAMP accumulation or by treatment with pure protein kinase A (PKA) [5] [6] [7] . The accumulation of ubiquitinated protein inclusions in neurodegenerative diseases 8 suggests that defects exist in 26S proteasomemediated clearance in affected neurons, and in support of this, tau from people with Alzheimer's disease has been shown to be polyubiquitinated at several sites [9] [10] [11] and several studies have implicated UPS dysfunction in response to tauopathy [12] [13] [14] [15] [16] [17] . Herein, we demonstrate that pharmacological agents that raise cAMP in the brain and activate PKA can phosphorylate proteasome subunits, enhance proteasome activity, promote clearance of abnormal tau and improve cognition.
RESULTS

Tau aggregation and accumulation of ubiquitin conjugates
We first investigated the impact of progressive tauopathy on the UPS in the rTg4510 mouse, which expresses a pathogenic tau mutation (P301L) and exhibits progressive neurofibrillary pathology, neuronal loss and cognitive deficits 18 . At 3-4 months, these mice model early-stage disease; by 8 months they resemble a more severe stage of the human disease. By 5 months, soluble tau migrating at ~55 kDa converts to a disease-associated, hyperphosphorylated insoluble tau species that migrates at ~64 kDa (Fig. 1a) . The ratio of 64-kDa to 55-kDa tau bands in cortical tissue (here referred to as the 64/55-kDa tau ratio) can be used to indicate the tauopathy stage of these mice. We observed the greatest change in the 64/55-kDa tau ratio in mice between 3 and 5 months of age, when the ratio increased fivefold. By 8 months, the 64/55 kDa tau ratio had increased further. Examination of additional time points (Supplementary Fig. 1a,b ) identified 3.5-4.5 months as the time at which 64-kDa tau first began to accumulate. The shift to 64-kDa forms coincided with an increase in the amount of sarkosyl-insoluble total and phosphorylated tau, a concomitant decrease in soluble (heat-stable) tau ( Fig. 1a and Supplementary  Fig. 1c ) and accumulation of total ubiquitinated proteins (Fig. 1a) .
Tauopathy decreases 26S proteasome activity
To assess whether worsening tauopathy impairs 26S proteasome function, we first measured the chymotrypsin-like activity of the 26S proteasomes. In older mice with a higher 64/55-kDa tau ratio, peptidase activity in the cortical brain extracts decreased. The activity of both singly (1-cap) and doubly (2-cap) capped 26S proteasomes decreased under these assay conditions; the free 20S particles showed no activity (Fig. 1b) . This decrease was not due to reduced 26S or 20S proteasome levels, as there was no change in the levels of the 26S proteasome regulatory subunit Rpt6 (Fig. 1b) or the 20S subunit (Supplementary Fig. 2a ).
Wild-type (WT) mice showed no decrease in 26S proteasome activity over this period (Supplementary Fig. 2b) .
To assay proteasome function more rigorously, we purified 26S proteasomes from mouse cortex by affinity chromatography using the ubiquitin-like domain (UBL) 19 . Purified proteasomes also showed a decrease in peptidase activity in mice between 3 and 5 months of age, coinciding with the period when levels of ~64 kDa tau increased. All three of the particle's peptidase activities-chymotrypsin- (Fig. 1c) , trypsin-and caspase-like activities (Supplementary Fig. 2c,e) decreased during this period. Peptidase activity of WT proteasomes was not affected up to 8 months of age ( Fig. 1d and Supplementary Fig. 2d,f) . Proteasomes from rTg4510 mice showed lower 26S peptidase activity than proteasomes from age-matched WT mice ( Supplementary Fig. 2g-i ) but no changes in 26S (2-cap and 1-cap) levels, as assessed by immunoblotting of native PAGE gel for the Rpt6 subunit (Supplementary Fig. 2g) , indicating that the decrease in 26S peptidase activity was related to tauopathy. Immunofluorescence labeling of human tau (red) and GFP signal (green, detected without antibody) in the frontal cortex of rTg4510:Ub-G76V-GFP and Ub-G76V-GFP mice at 5 (g) and 8 (h) months of age. Insets, high-magnification views of outlined areas. Scale bars, 50 µm. (i) Quantification of GFP puncta from analyses in g and h. Control, 5-month-old rTg4510: Ub-G76V-GFP. (j) Immunoblot analysis of GFP expression in rTg4510:Ub-G76V-GFP and Ub-G76V-GFP mice. For a,b and j at least three biological experiments (two mice per experiment, n = 6 mice) were performed. For c-f, n = 6 cortical brains per age group were used to elute 26S proteasomes, and at least three independent experiments were performed. Quantification of GFP signal for g and h was performed on slices from 6 mice per group. Error bars, mean ± s.e.m.; n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA followed by Tukey's multiple comparison post hoc test).
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Ubiquitinated proteins are the primary substrates of 26S proteasomes in cells. Therefore, to obtain a more physiologically relevant measure of proteasome function in rTg4510 mice, we measured the degradation rates of two well-characterized substrates, ubiquitinated DHFR (Ub5-DHFR) and ubiquitinated Sic1 (Ub n -Sic1) 20, 21 . Proteasomes from rTg4510 mice aged 5 and 8 months showed a reduced capacity to hydrolyze these ubiquitin conjugates, compared to proteasomes from 3-month-old rTg4510 or age-matched WT mice ( Fig. 1e and Supplementary Fig. 2j) .
ATP hydrolysis by the six AAA+ ATPases of the 19S regulatory particles is crucial for substrate degradation 20, 22, 23 . To examine the function of ATPase subunits, we measured ATP hydrolysis 20, 23 of purified proteasomes from WT and rTg4510 mice. Proteasomes from 8-month-old rTg4510 mice showed reduced ATP hydrolysis, as compared to age-matched WT proteasomes (Fig. 1f) , but the difference between rTg4510 and WT was not significant at 3 months.
To obtain additional evidence that worsening tauopathy is associated with proteasome dysfunction, we generated a transgenic mouse by crossing rTg4510 mice to a UPS reporter line expressing a 26S-targeted fragment fused to GFP 24 . Normally, the fusion protein is ubiquitinated and hydrolyzed rapidly by the 26S proteasome via the ubiquitin-fusion degradation (UFD) pathway 20 . GFP is therefore undetectable (or present at very low levels) in normal cells, but it is stabilized and accumulates when there are defects in the UPS. The transgenic (rTg4510:Ub-G76V-GFP) mice showed accumulation of GFP puncta, which increased with worsening tauopathy from 5 ( Fig. 1g ) to 8 months (Fig. 1h) . In contrast, the brains of littermate mice expressing Ub-G76V-GFP but not mutant tau (Ub-G76V-GFP mice) accumulated very low amounts of GFP at both 5 ( Fig. 1g) and 8 (Fig. 1h) months, although there was a slight (nonsignificant) increase with age. Quantitative analysis of GFP by immunohistochemistry ( Fig. 1i) and immunoblotting ( Fig. 1j) showed more GFP in rTg4510:Ub-G76V-GFP mice than in age-matched Ub-G76V-GFP controls. The GFP signal was often localized in the cell body and appeared to overlap with human tau, which is predominantly somatodendritic at 5-8 months. However, in the rTg4510:Ub:G76V-GFP mice, the intensity of tau staining resulting from the high level of tau expression made it difficult to observe GFP signal in the same cells. We therefore examined a second mouse line (JNPL3, which carry a human tau with a P301L mutation 25 , crossed to Ub-G76V-GFP mice). Hindbrain neurons from the resulting JNPL3:Ub-G76V-GFP mice showed colocalization of tau and GFP ( Supplementary Fig. 3 ), probably owing to co-sequestration of aggregated tau and GFP into inclusion bodies.
To confirm that the accumulation of tau aggregates and not soluble tau impairs proteasome function, we generated stable lines of human embryonic kidney (HEK) cells expressing WT tau or highly aggregable mutant tau. The cell lines expressed similar amounts of soluble tau, but the mutant line showed higher amounts of insoluble tau (Fig. 2a) . The chymotrypsin-like activity of 26S proteasomes from tau mutantexpressing cells was lower than that in WT-expressing cells, which was not different from that in nontransfected, control cells (Fig. 2b) .
Protein aggregates that cause neurodegenerative diseases have been proposed to physically associate with proteasomes and interfere with substrate degradation 26 . Immunoprecipitation of human tau from cortical brain extracts of rTg4510 mice aged 3, 5 or 8 months (Fig. 2c) co-precipitated several proteasome subunits.
To test whether aggregates of tau can directly cause proteasome dysfunction, we incubated proteasomes with recombinant monomeric tau or aggregates 27 . Incubation of 26S proteasomes from WT mice with low-molecular weight (LMW) oligomeric or fibrillar tau reduced peptidase activity, whereas incubation of 26S proteasomes with monomeric tau had no effect (Fig. 2d) . To examine the effect of LMW forms of tau, we incubated recombinant tau for 8, 24 or 48 h and then incubated equivalent amounts of each oligomers preparation with purified Untreated WT 26S proteasomes were used as a control for d and e. At least three biological replicates were performed with stably transfected clones (a,b). For immunoprecipitation (c), two animals per experiment were analyzed in three biological replicates (n = 6 mice). Purified proteasomes from n = 6 brains from 3-month-old WT were used for d and e, and at least three independent experiments were performed (d,e). Error bars, means ± s.e.m. *P < 0.05, **P < 0.01 (one-way ANOVA followed by Tukey's multiple comparison post hoc test).
npg proteasomes. Tau monomers had no effect, but oligomers incubated for 48 h impaired proteasome function significantly (Fig. 2e) .
Enhanced proteasome activity via cAMP-PKA attenuates tauopathy PKA enhances proteasome peptidase activity 5, 6 . Therefore, we tested whether raising levels of cAMP and activating PKA would stimulate proteasome activity ex vivo (Fig. 3) and in vivo (Figs. 4 and 5) .
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo 28 . To assess whether activation of cAMP-PKA enhances proteasome function and reduces the accumulation of tau, we prepared cortical brain slices from rTg4510 mice aged 3-4 months (early-stage mice) and treated them with vehicle, dibutyryl-cAMP (db-cAMP), rolipram or epoxomicin (a specific inhibitor of the proteasome's chymotrypsinlike activity). Exposure of slices from the early-stage mice to rolipram or db-cAMP for 8 h reduced amounts of total and insoluble tau (Fig. 3a) , including phosphorylated tau ( Supplementary Fig. 4a,b) . In contrast, epoxomicin treatment increased levels of phosphorylated tau ( Supplementary Fig. 4 ), although the amount of total tau remained unchanged (Fig. 3a) . PKA is known to phosphorylate tau at Ser214 (pS214) 29 . We therefore monitored the amount of pS214 tau to determine whether rolipram and db-cAMP activated PKA. The amount of pS214 tau was higher in db-cAMP-and rolipramtreated samples than in control (DMSO) and epoxomicin-treated slices (Fig. 3a) . The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin (Fig. 3b) .
To verify that these effects were mediated through enhancement of proteasomal activity and not some other effect of cAMP-PKA, we treated organotypic slices from early-stage rTg4510 mice with epoxomicin and db-cAMP or rolipram (Fig. 3c) . Epoxomicin prevented the decrease in total and insoluble tau seen with db-cAMP and rolipram treatment alone. pS214 tau has been shown to reduce recombinant tau aggregation in vitro 30, 31 . However, in acute organotypic slices, hyperphosphorylation of Ser214 by db-cAMP or rolipram occurred in the presence of epoxomicin but without a reduction in tau aggregates (Fig. 3c) .
Phosphorylation of proteasomes protects against tau toxicity
To further confirm that the impact of enhanced PKA activity was on proteasome function and phosphorylation, we incubated purified 26S proteasomes from WT mouse brains with active PKA for 60 min and assayed their chymotrypsin-like activity. PKA treatment enhanced proteasome activity almost twofold (Fig. 3d) . Proteasomes incubated with oligomeric tau showed a reduced rate of hydrolysis of the small fluorogenic peptide (Fig. 3d) , but proteasomes pre-treated with PKA were protected from the inhibitory effect of tau oligomers, as the decrease in activity in PKA-treated proteasomes after the addition of oligomers was not statistically significant (Fig. 3d) . WT proteasomes incubated with LMW oligomeric tau showed a reduced rate of hydrolysis of Ub5-DHFR (Fig. 3e) and a decrease in ATP hydrolysis (Fig. 3f) , as compared to proteasomes without added oligomers. Pre-treatment of proteasomes with PKA enhanced degradation of Ub5-DHFR (Fig. 3e) and ATP hydrolysis (Fig. 3f) and protected against the inhibitory effect of oligomers on these activities (Fig. 3e,f) . Thus PKA treatment appeared to protect proteasomes from the inhibitory effects of aggregated tau in vitro. PKA treatment led to an increase in phosphorylation of proteasome particles For a-c, two animals per experiment were analyzed in three biological replicates (n = 6 mice). For d-g, purified proteasomes from n = 6 brains from 3-month-old WT mice were used for each hydrolyzing assay and at least three independent experiments were performed. Error bars, mean ± s.e.m.; n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA followed by Tukey's multiple comparison post hoc test).
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( Fig. 3g) , supporting the idea that proteasome activation by PKA is mediated by phosphorylation of proteasome subunits. Analyses of the mechanisms involved in proteasome activation by PKA are presented in Lokireddy et al. 32 .
Rolipram enhances proteasome activity and reduces tauopathy
To test whether raising cAMP with rolipram could reduce tauopathy and cognitive impairment, we administered rolipram to rTg4510 and rTg4510:Ub-G76V-GFP mice. Rolipram treatment during earlystage tauopathy in rTg4510 mice reduced amounts of total ( Fig. 4a and Supplementary Fig. 5a ) and phosphorylated tau (Fig. 4c,e and Supplementary Fig. 5b,c) in both the crude extracts and the insoluble fraction. The soluble (heat-stable) tau species also decreased slightly but not significantly. Rolipram treatment increased the total amount of pS214 tau in the extracts, confirming that PKA activity was enhanced (Supplementary Fig. 5d ).
To assess whether rolipram treatment attenuated UPS deficits in vivo, we also treated rTg4510:Ub-G76V-GFP mice. Rolipram-treated rTg4510:Ub-G76V-GFP mice showed reduced immunofluorescence labeling of total and phosphorylated tau (Fig. 4b,d,f) . Because tau aggregates were reduced, we also measured p62 protein, which associates with insoluble ubiquitinated proteins after proteasome inhibition 33 . Rolipram treatment significantly decreased p62 levels in rTg4510:Ub-G76V-GFP mice, as assessed by immunofluorescence staining (Fig. 4g) , and in rTg4510 mice, as assessed by quantitative immunoblotting (Fig. 4h and Supplementary Fig. 5e ).
GFP (an indicator of UPS dysfunction) was reduced as assessed by detection of fluorescence without antibody ( Fig. 5a and Supplementary Fig. 6a ) and by immunoblotting (Fig. 5b) in the CA1 region of the hippocampus and in the cortex of rTg4510: Ub-G76V-GFP mice treated with rolipram. Age-matched control mice (Ub-G76V-GFP) showed no change in the amount of GFP between vehicle-and rolipram-treated animals, as assessed by immunoblotting (Supplementary Fig. 6b) , and no accumulation of GFP puncta when analyzed by confocal microscopy for GFP signal ( Supplementary  Fig. 6c ). These findings indicate that rolipram treatment improved UPS-mediated degradation in mice with tauopathy in vivo. In support of these findings, when 26S proteasomes from the brains of these ), slices from 6 mice per treatment group were analyzed. Error bars, mean ± s.e.m.; n.s., not significant; *P < 0.05, ***P < 0.001 (unpaired two-tailed Student's t-test). Vehicle treatment served as control for all experiments. npg mice were resolved by native PAGE, both doubly capped and singly capped 26S particles showed increased activity in rolipram-treated mice ( Fig. 5c and Supplementary Fig. 7a ). The levels of proteasome proteins were unchanged (Supplementary Fig. 7b ). Purified proteasomes from rolipram-treated mice had increased chymotrypsin- (Fig. 5d) , trypsin-and caspase-like activities ( Supplementary  Fig. 8a,b) , and the amount of ubiquitinated proteins was lower in extracts from rolipram-treated mice, consistent with enhanced proteasome activity ( Fig. 5e and Supplementary Fig. 7c ).
To assess whether the mechanism of enhanced serine and threonine phosphorylation of proteasome subunits could occur in rolipram-treated mice in vivo as observed in 26S proteasomes treated with purified PKA (Fig. 3e) , we purified 26S particles from vehicle-(control) and rolipram-treated rTg4510 mouse brains and analyzed them by quantitative immunoblotting with an antibody to phosphorylated serines and threonines. Increased phosphorylation of serine and threonine epitopes of several subunits was evident in the rolipram-treated group (Fig. 5f) , without any change in protein levels of proteasomes (Fig. 5g) .
To assess whether rolipram treatment could protect proteasomes from tau-mediated inhibition, we isolated 26S proteasomes from rolipram-treated mice and incubated them with tau oligomers.
Inhibition was not significant after rolipram-treated 26S proteasomes were incubated with tau oligomers (Fig. 5h) , unlike the marked inhibition seen in proteasomes from untreated WT mice incubated with oligomers (Fig. 3d) . Pre-incubation of proteasomes from rolipram-treated rTg4510 mice with PKA further increased proteasome phosphorylation (Fig. 5i) , and peptidase activity was increased (Fig. 5h) , suggesting that further activation was possible even in the presence of tau oligomers.
cAMP-PKA signaling has been shown to suppress autophagy induction and autophagy-dependent neurite degeneration in primary neuronal cells bearing an LRRK2 mutation 34 . In our study, rolipram administration in rTg4510 mice had no effect on the levels of proteins associated with autophagic induction or on proteins responsible for elongation and maturation of the autophagosome (Supplementary Fig. 9 ).
Rolipram improves cognition in early-stage tauopathy
To assess the effect of rolipram on tauopathy-associated cognitive impairment, we examined spatial reference memory in rTg4510, rTg4510:Ub-G76V-GFP and WT mice in the Morris water maze. We observed a difference between WT and rTg4510 mice (genotype and for quantification of GFP signal (n = 3 mice per treatment group) (a) were carried out using unpaired two-tailed Student's t-test between groups. Purified proteasomes were pooled from n = 6 brains (d, f-i), and at least three independent experiments were performed. Statistical analyses employed two-tailed Student's t-test between groups (d) and one-way ANOVA followed by Tukey's multiple comparison post hoc test (h). Error bars, mean ± s.e.m.; n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001. Veh, vehicle; rolip, rolipram.
npg effect) and between treated and untreated (vehicle or rolipram) rTg4510 mice (treatment effect) on spatial learning over time ( Fig. 6 and Supplementary Data). Escape latency at day 3 was not different across treatment groups for any strains tested. However, by day 4 of testing, cognitive impairment was detectable in vehicle-treated rTg4510 mice but not in rolipram-treated rTg4510 mice or WT groups, and the performance of rolipram-treated rTg4510 mice did not differ from that of WT mice. Rolipram treatment had the same effect in rTg4510:Ub-G76V-GFP mice (data not shown). This effect could not be attributed to a general improvement in cognition or performance, as rolipram treatment had no effect on the performance of WT mice.
Rolipram treatment is not effective in late-stage disease Rolipram was not as effective at later stages of tauopathy (age 8-10 months in rTg4510 mice) as at 3-4 months, either ex vivo ( Supplementary Fig. 10 ) or in vivo (Supplementary Fig. 11 ). In contrast to our observations in slices from early-stage mice, acute slices from cortex of mice with advanced tauopathy showed only a slight (not significant) decrease in total (Supplementary Fig. 10a ) and phosphorylated ( Supplementary Fig. 10b,c) tau levels after treatment with db-cAMP or rolipram. There was a trend toward increased proteasome activity upon exposure to db-cAMP or rolipram, but this was not statistically significant ( Supplementary Fig. 10d ), and activity was lower than that evoked in slices from early-stage brains. PKA activity (indicated by the level of pS214 tau) was increased after db-cAMP or rolipram treatment, but the change reached significance only after db-cAMP treatment (Supplementary Fig. 10e ). In agreement with our findings ex vivo, rolipram administration in late-stage mice did not reduce the levels of total (Supplementary Fig. 11a ) or phosphorylated tau (Supplementary Fig. 11b,c) . The levels of ubiquitinated proteins were not significantly different in late-stage mice treated with vehicle and rolipram (Supplementary Fig. 11e) . Furthermore, neither the activity of proteasomes nor the levels of proteasome proteins (Supplementary Fig. 11f ) were significantly different. In vivo phosphorylation of 26S proteasome was lower in late-stage rolipram-treated rTg4510 mice than in early-stage, rolipram-treated mice (Supplementary Fig. 11g ). Spatial learning was not improved in late-stage rTg4510 mice after rolipram treatment ( Supplementary  Fig. 12a and Supplementary Data). As PKA-mediated phosphorylation and activation of cAMP response element-binding protein (CREB) has been shown to lead to memory improvement 35 , we wanted to assess whether CREB was phosphorylated by rolipram.
We assessed the amount of phosphorylated and total CREB in tissue lysates from vehicle-and rolipram-treated rTg4510 mice, and found that phosphorylated CREB was increased in early-and late-stage rolipram-treated mice (Supplementary Fig. 12b,c) . As we observed cognitive improvement only in rolipram-treated early-stage mice, it is unlikely that the activation of CREB signaling by cAMP-PKA accounted for the improved cognition.
DISCUSSION
The degradation of ubiquitin conjugates by the 26S proteasome is coupled to ATP hydrolysis 36 , and ATP enhances multiple steps in this process, including conjugate binding, deubiquitination, substrate unfolding, gate opening in the 20S particle 22, 37 and substrate translocation into the 20S central chamber 21 . Protein aggregates, such as tau, that bind the 26S particle but resist dissociation or translocation through the ATPases, could disrupt this multistep process and obstruct the degradation of other proteins. In support of this, defects in proteasomal degradation of ubiquitinated proteins have been observed in the brains of mice infected with the prion protein PrP Sc (ref. 26) , and microaggregates of PrP Sc were shown to directly bind to 20S core particles and interfere with ATPase-induced gate opening for substrate entry 26 , leading to reduced hydrolysis of peptides, as we have shown for tau. It has generally been assumed that the rate-limiting step in the UPS is substrate ubiquitination and that the proteasome digests all ubiquitinated proteins that bind to it. However, recent findings indicate that many ubiquitinated proteins bind the proteasome but are released (or deubiquitinated and released) without degradation 2, 36, 38 . In proteotoxic diseases, a larger fraction of ubiquitin conjugates may fail to be digested. Similarly to a Huntington's disease model 39 , PKA-mediated phosphorylation in the tauopathy model may enhance the fraction of ubiquitinated proteins that bind and are degraded 36, 40 . Our in vitro studies showed that enhancement of proteasome activity by cAMP-PKA caused a rapid drop in ubiquitin conjugate levels, strongly suggesting that PKA-induced enhancement of conjugate degradation was responsible for the enhanced tau clearance. Thus, the rate of protein breakdown in cells appears to be regulated by proteasome phosphorylation and not just by substrate ubiquitination 32 .
Of particular note in the present study was the ability of a pharmacological agent to promote proteasome activity, reduce tau and ameliorate disease-associated cognitive defects through cAMP-PKA signaling in mice during early-stage disease. However, short-term cAMP-PKA activation in mice at later stages of disease did not have the same effect. It is possible that this was a result of the short (3-week) exposure to rolipram or of suboptimal dosing of the mice, which have a very robust tauopathy phenotype. Alternatively, the form of tau cleared by the UPS might be the form involved in cell-to-cell propagation of tauopathy, and prevention of propagation of this form of tau by rolipram might be apparent only in a mouse model, where propagation of the disease can be quantified 41, 42 .
We have shown that enhanced cAMP-PKA signaling in vivo leads to phosphorylation of several proteins in purified proteasomes leading to and that phosphorylation of critical proteasome subunits (particularly Rpn6) enhanced peptide and conjugate breakdown and ATPase function 32 . cAMP and PKA activate many other cellular processes, but enhancement of protein breakdown by phosphorylation of the proteasome is a new action for cAMP signaling. npg Together, these findings point to enhancement of proteasomal function through agents that phosphorylate proteasome subunits as a potentially promising therapeutic approach to treatment of proteotoxic diseases.
METhODS
Methods and any associated references are available in the online version of the paper. 
